| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED FEBRUARY 2015. Refer to TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | golimumab (Simponi®) | |
| Formulation | 50 mg solution for injection, 100 mg solution for injection | |
| Reference number | 1323 | |
| Indication | Treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies |
|
| Company | Merck Sharp & Dohme Ltd | |
| BNF chapter | Gastro-intestinal system | |
| Submission type | Non-submission | |
| Status | Superseded | |
| Ratification by Welsh Government | 26/02/2014 | |
| Date of issue | 27/02/2014 | |
| NICE guidance | ||